Abstract
The present study is an investigation of the safety and immunogenicity of DNA and modified vaccinia virus Ankara (MVA) candidate vaccines, each encoding the malaria DNA sequence multiple epitope-thrombospondin related adhesion protein (ME-TRAP), against Plasmodium falciparum. DNA ME-TRAP and MVA ME-TRAP are safe and immunogenic for effector and memory T cell induction. MVA ME-TRAP, with or without prior DNA ME-TRAP immunization, was more immunogenic and more cross-reactive in malaria-exposed individuals than in malaria-naive individuals, a finding suggesting that recombinant MVA vaccines are particularly promising for the development of a malaria vaccine for exposed populations. Both CD4(+) and CD8(+) T cells were induced by these vaccines.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Africa
-
Animals
-
CD4-Positive T-Lymphocytes / immunology
-
CD8-Positive T-Lymphocytes / immunology
-
Humans
-
Immunization Schedule
-
Lymphocyte Activation
-
Malaria Vaccines / administration & dosage
-
Malaria Vaccines / adverse effects*
-
Malaria Vaccines / immunology*
-
Malaria, Falciparum / immunology
-
Malaria, Falciparum / prevention & control
-
Plasmodium falciparum / immunology
-
Protozoan Proteins / genetics
-
Protozoan Proteins / immunology
-
Vaccines, DNA / administration & dosage
-
Vaccines, DNA / adverse effects*
-
Vaccines, DNA / immunology*
-
Vaccinia virus / genetics*
Substances
-
Malaria Vaccines
-
Protozoan Proteins
-
Vaccines, DNA
-
thrombospondin-related adhesive protein, protozoan